Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Summary

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

Eligibility

Inclusion Criteria:

1. Patients more than 20 years old
2. Chronic hepatitis B patients
3. Patients who were indicated for hepatitis B virus antiviral therapy

Exclusion Criteria:

1. Decompensated liver disease (Child-Pugh B \&C)
2. End stage renal disease (eGRF \< 15 ml/min/1.73m2)
3. Prior use of nucleot(s)ide analogues for chronic hepatitis B
4. Prior use of interferon for chronic hepatitis B within six months
5. Known history of human immunodeficiency virus or hepatitis C virus co-infection
6. Concurrent other uncontrolled malignancy
7. Women in pregnancy or lactation
8. Cannot conform to the study protocol of this study

Conditions3

Interventions2

Related trials

• Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors — University Health Network, Toronto
• Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers — Sun Yat-sen University
• Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF — Third Affiliated Hospital, Sun Yat-Sen University
• The HOPE Study: Characterizing Patients With Hepatitis B and C — University of Maryland, Baltimore

Browse More Trials